TY - JOUR
T1 - Transplant glomerulopathy
T2 - Subclinical incidence and association with alloantibody
AU - Gloor, J. M.
AU - Sethi, S.
AU - Stegall, M. D.
AU - Park, W. D.
AU - Moore, S. B.
AU - DeGoey, S.
AU - Griffin, M. D.
AU - Larson, T. S.
AU - Cosio, F. G.
PY - 2007/9
Y1 - 2007/9
N2 - Transplant glomerulopathy (TG) usually has been described as part of a constellation of late chronic histologic abnormalities associated with proteinuria and declining function. The current study used both protocol and clinically-indicated biopsies to investigate clinical and subclinical TG, their prognosis and possible association with alloantibody. We retrospectively studied 582 renal transplants with a negative pre-transplant T-cell complement dependent cytotoxicity crossmatch. TG was diagnosed in 55 patients, 27 (49%) based on protocol biopsy in well-functioning grafts. The cumulative incidence of TG increased over time to 20% at 5 years. The prognosis of subclinical TG was equally as poor as TG diagnosed with graft dysfunction, with progressive worsening of histopathologic changes and function. Although TG was associated with both acute and chronic histologic abnormalities, 14.5% of TG biopsies showed no interstitial fibrosis or tubular atrophy, while 58% (7/12) of biopsies with severe TG showed only minimal abnormalities. TG was associated with acute rejection, pretransplant hepatitis C antibody positivity and anti-HLA antibodies (especially anti-Class II), with the risk increasing if the antibodies were donor specific. We suggest that subclinical TG is an under-recognized cause of antibody-mediated, chronic renal allograft injury which may be mechanistically distinct from other causes of nephropathy.
AB - Transplant glomerulopathy (TG) usually has been described as part of a constellation of late chronic histologic abnormalities associated with proteinuria and declining function. The current study used both protocol and clinically-indicated biopsies to investigate clinical and subclinical TG, their prognosis and possible association with alloantibody. We retrospectively studied 582 renal transplants with a negative pre-transplant T-cell complement dependent cytotoxicity crossmatch. TG was diagnosed in 55 patients, 27 (49%) based on protocol biopsy in well-functioning grafts. The cumulative incidence of TG increased over time to 20% at 5 years. The prognosis of subclinical TG was equally as poor as TG diagnosed with graft dysfunction, with progressive worsening of histopathologic changes and function. Although TG was associated with both acute and chronic histologic abnormalities, 14.5% of TG biopsies showed no interstitial fibrosis or tubular atrophy, while 58% (7/12) of biopsies with severe TG showed only minimal abnormalities. TG was associated with acute rejection, pretransplant hepatitis C antibody positivity and anti-HLA antibodies (especially anti-Class II), with the risk increasing if the antibodies were donor specific. We suggest that subclinical TG is an under-recognized cause of antibody-mediated, chronic renal allograft injury which may be mechanistically distinct from other causes of nephropathy.
KW - Alloantibodies
KW - Chronic allograft nephropathy (CAN)
KW - Chronic transplant glomerulopathy
KW - Humoral rejection
KW - Protocol biopsies
KW - Transplant glomerulopathy
UR - http://www.scopus.com/inward/record.url?scp=34547850861&partnerID=8YFLogxK
U2 - 10.1111/j.1600-6143.2007.01895.x
DO - 10.1111/j.1600-6143.2007.01895.x
M3 - Article
C2 - 17608832
AN - SCOPUS:34547850861
SN - 1600-6135
VL - 7
SP - 2124
EP - 2132
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 9
ER -